Effect of Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The intervention will involve administration of external beam radiotherapy (5 fractions of 2Gy) focused to the heart.
Measurements of effect will be assessed at 12 weeks by:
Amyloid PET Cardiac MRI with administration of gadolinium and ultrasound A blood venous sample (cardiac biomarkers) Quality of life assessments
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: René Nkoulou, Dr.
- Phone Number: +41 22 37 27 196
- Email: rene.nkoulou@hcuge.ch
Study Contact Backup
- Name: Philippe Meyer, Dr.
- Phone Number: +41 22 37 27 225
- Email: philippe.meyer@hcuge.ch
Study Locations
-
-
-
Geneva, Switzerland, 1205
- Recruiting
- Geneva University Hospital
-
Contact:
- René Nkoulou, Dr.
- Email: rene.nkoulou@hcuge.ch
-
Principal Investigator:
- René Nkoulou
-
Sub-Investigator:
- Philippe Meyer
-
Sub-Investigator:
- Thomas Zillli
-
Sub-Investigator:
- Valentina Garibotto
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >65 y.o.
- Dyspnoea on exertion (NYHA II or more).
- Stable elevated cardiac enzymes (ultra sensitive Troponin T > 14 ng/L on consecutive sampling or BNP > 100pg/mL)
- A positive 99mTc-DPD cardiac scintigraphy (Grade 2 and 3) suggesting an ATTR or wt amyloidosis.
- Additional imaging also compatible with cardiac amyloidosis (cardiac ultrasound showing basal to apical longitudinal strain gradient and magnetic resonance imaging with elevated T1 value or extracellular volume).
- Compliance with the informed consent as attested by its signature.
- Positive baseline 18F-Florbetapir imaging, as assessed visually and quantitatively by a Tissue to Background Ratio > 1.45
Exclusion Criteria:
- Positive serum protein immunoelectrophoresis with monoclonal gammapathy.
- Previous external beam radiotherapy including the chest.
- Claustrophobia
- Presence of internal non-MR compatible devices
- Creatinine glomerular filtration rate < 30 ml/min
- Oncologic disease (excluding skin cancer) active or in remission from less than 5 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Singe arm
Subjects will receive a low dose radiotherapy focused to the heart
|
10 Gy in 5 fractions of 2 Gy on 5 consecutive days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of the degree of amyloid
Time Frame: 12 weeks
|
Assess intra-individual change in a quantitative measure of amyloid deposits on 18F-Amyloid (Standard Uptake Value ratio) SUVR between amyloid PET scans before and after low dose RT
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and adverse event associated with cardiac low dose RT
Time Frame: 6 months
|
Assess the number of patients who report adverse events
|
6 months
|
|
Modification in echocardiographic global longitudinal strain
Time Frame: 6 months
|
Assess intra-individual change in a quantitative measures
|
6 months
|
|
Modification in MRI extracellular volumes and T1 values
Time Frame: 12 weeks
|
Assess intra-individual change in a quantitative measures
|
12 weeks
|
|
Modification in cardiac biomarker (ultrasensitive troponin T and BNP blood levels) features of cardiac amyloidosis
Time Frame: 6 months
|
Assess intra-individual change in a quantitative measures
|
6 months
|
|
Modification of quality of life
Time Frame: 6 months
|
The quality of life will be assessed by the SF-36 short form health survey quality of life scale
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2017-00640
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.